By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Fresh data on Neuropathy are presented in a new report. According to news reporting originating in Cagliari, Italy, by NewsRx journalists, research stated, "The objectives of this study were to evaluate the risk of neuropathy in patients with Parkinson's disease (PD) and to evaluate the role of levodopa exposure as a potential risk factor. A multicenter study of 330 patients with PD and 137 healthy controls with a comparable age distribution was performed."
The news reporters obtained a quote from the research from the University of Cagliari, "With respect to levodopa exposure, 144 patients had long exposure (3 years) to levodopa (LELD), 103 patients had short exposure (<3 years) to levodopa (SELD), and 83 patients had no exposure to levodopa (NOLD). Nerve function was evaluated using the reduced total neuropathy score. Right sural sensory antidromic and peroneal motor nerve conduction studies were performed by neurophysiologists who were blinded to the existence of neuropathy clinical features or PD treatment. Overall, 19.40% of patients in the LELD group, 6.80% in the SELD group, 4.82% in the NOLD group, and 8.76% in the control group were diagnosed with neuropathy (axonal, predominantly sensory). Multivariate logistic analysis indicated that the risk of neuropathy was not influenced by disease duration, severity, or sex. The risk of neuropathy increased by approximately 8% for each year of age (P <0.001; odds ratio [OR], 1.08; 95% confidence interval [CI], 1.037-1.128). The risk of neuropathy was 2.38 higher in the LELD group than in the control group (P=0.022; OR, 2.38; 95% CI, 1.130-5.014). In a comparison between patients with and without neuropathy (Student's t test), the levodopa dose was higher (P <0.0001), serum vitamin B12 levels were lower (P=0.0102), and homocysteine levels were higher (P <0.001) in the patients with neuropathy. Our results demonstrate that the duration of exposure to levodopa, along with age, is the main risk factor for the development of neuropathy."
According to the news reporters, the research concluded: "Screening for homocysteine and vitamin B12 levels and clinical-neurophysiological monitoring for neuropathy may be advisable in patients with PD who are receiving treatment with levodopa."
For more information on this research see: Neuropathy and Levodopa in Parkinson's Disease: Evidence From a Multicenter Study. Movement Disorders, 2013;28(10):1391-1397. Movement Disorders can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Movement Disorders - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1531-8257)
Our news correspondents report that additional information may be obtained by contacting R. Ceravolo, University of Cagliari, Dept. of Public Hlth Univ Clin & Mol Med, Cagliari, Italy. Additional authors for this research include G. Cossu, M.B. di Poggio, L. Santoro, P. Barone, M. Zibetti, D. Frosini, V. Nicoletti, F. Manganelli, R. Iodice, M. Picillo, A. Merola, L. Lopiano, A. Paribello, D. Manca, M. Melis, R. Marchese, P. Borelli, A. Mereu and Contu (see also Neuropathy).
Keywords for this news article include: Italy, Cagliari, Levodopa, Treatment, Neuropathy, Amino Acids, Brain Diseases, Movement Disorders, Parkinson's Disease, Risk and Prevention, Basal Ganglia Diseases, Dihydroxyphenylalanine, Parkinsonian Disorders, Neurodegenerative Diseases, Central Nervous System Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.